Molsidomine Eg (Molsidomine)

Molsidomine is a prodrug that is converted in the body to a nitric‑oxide donor. The released nitric oxide activates soluble guanylate cyclase, raising cyclic GMP levels in vascular smooth‑muscle cells. This cascade causes smooth‑muscle relaxation, vasodilation, and a reduction in cardiac preload and afterload, which together lessen the heart’s oxygen requirement.

The dosage of Molsidomine is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. The prescriber determines the appropriate strength, frequency, and duration, and patients should follow the specific instructions provided on the prescription label.

Safety data for Molsidomine in pregnancy and lactation are limited. Because potential risks cannot be ruled out, it is generally advised to avoid use unless the expected benefit justifies the potential hazard to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Molsidomine Eg. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Molsidomine differs from traditional nitrates in that it releases nitric oxide more gradually, offering a smoother onset of action and fewer rapid peaks that can cause tolerance. Compared with beta‑blockers, it directly dilates vessels rather than reducing heart rate, making it useful when heart‑rate‑lowering agents are contraindicated. Its safety profile is generally favorable, though hypotension remains a key consideration.

Molsidomine should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments. No special refrigeration is required for this oral formulation.

Molsidomine is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals. Swallow the tablet whole; do not crush, chew, or split it unless specifically instructed by a healthcare professional.

The most serious adverse events include severe hypotension, which can lead to fainting or syncope, and rare allergic reactions such as Stevens‑Johnson syndrome. Patients should be alert for sudden drops in blood pressure, dizziness, loss of consciousness, or any signs of a severe skin rash, and seek immediate medical attention if these occur.

Molsidomine is contraindicated in patients with known hypersensitivity to the drug or its excipients, those with severe hypotension, and individuals taking other potent vasodilators such as nitrates or phosphodiesterase‑5 inhibitors without close medical supervision. Caution is also advised in patients with significant hepatic impairment or decompensated heart failure.